Not broadly. As of October 8, 2026, a limited group of marijuana products had been placed in Schedule III, but the wider proposal to move marijuana from Schedule I to Schedule III had not been finalized in the official materials reviewed. The broad proceeding was reportedly paused on September 29 while an administrative law judge considered a motion.
Did the DEA reschedule marijuana?
The answer depends on which action you mean. On April 23, 2026, the Department of Justice announced a limited Schedule III action for FDA-approved products containing marijuana and marijuana products covered by qualifying state medical marijuana licenses. That action is distinct from the broader proposal to transfer marijuana from Schedule I to Schedule III.
The DEA’s regulatory-actions page describes the broader measure as a proposed rule and hearing process. The latest reports available by October 8 say those proceedings were paused, not completed. Neither the judge’s recommendation nor a final agency decision had been established in the materials reviewed.
Which marijuana products moved to Schedule III?
The April 2026 action covers two specified categories: FDA-approved products containing marijuana, and marijuana products regulated under qualifying state medical marijuana licenses. The DOJ’s announcement describes that limited action and separately addresses the broader rescheduling process.
Recommended Free Tools
#1 Best Overall
It does not establish that every product sold in a state medical-marijuana market qualifies, and it does not automatically cover recreational products. The scope turns on the categories identified in the federal action, not simply on whether a product is sold in a state where marijuana is permitted.
What is the status of the broader Schedule I-to-III proposal?
The broader process began with a May 21, 2024, notice of proposed rulemaking. A proposed rule is a step in agency rulemaking, not a final change in federal scheduling.
DEA set formal proceedings on the broader proposal for June 29 through July 15, 2026. Its hearing notice gives the schedule and procedural background. According to Regulatory Oversight’s October 5 report and NORML’s October 1 report, Chief Administrative Law Judge Derek C. Julius paused the proceeding on September 29 while considering a motion about admitting a September Government Accountability Office report and allowing supplemental briefing.
The reports said the government’s response to the motion was due October 13, 2026. That deadline was still in the future as of October 8, so its outcome—and any later recommendation or agency decision—should not be treated as known.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchRank #3
What does Schedule III mean for legality?
Schedule III is a category under the federal Controlled Substances Act, not a synonym for legal, harmless, or unrestricted. Rescheduling is also different from descheduling. The DOJ characterized the April action as maintaining strict federal controls, and the wider proposal remains a separate process.
- The limited April action applies only to the product categories specified by DOJ.
- It does not mean recreational marijuana was legalized federally.
- It does not mean all state-market marijuana products were automatically moved to Schedule III.
Why did federal officials propose rescheduling?
The rationale traces to a recommendation from the Department of Health and Human Services. On August 29, 2023, HHS Assistant Secretary for Health Rachel L. Levine recommended Schedule III. The 2024 proposed rule summarized HHS’s assessment that marijuana had a currently accepted medical use, lower abuse potential than Schedule I and II substances, and the potential for moderate or low physical dependence or high psychological dependence.
The 2024 proposed rule also distinguished HHS’s recommendation from DEA’s own determination: at that point, DEA said it had not yet made one. The recommendation formed the basis for considering a change; it was not itself a final scheduling decision.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What should consumers and businesses watch next?
The next dated procedural milestone reported as of October 8 was the government’s October 13 response deadline concerning the motion to admit the GAO report and allow additional briefing. The stay reports do not establish what the judge will recommend after considering the motion, or when the broader process will reach a final agency decision.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesBest Value
For now, distinguish the April 2026 product-specific action from the unresolved broader proposal. For a particular product or business, the decisive question is whether it falls within the categories covered by the DOJ action—not whether marijuana has been rescheduled in general.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
